For this gene in particular, we validated that different tumor cell lines may indeed not all be equally dependent on TRAF2 for their immune resistance, with some cell lines relying (more) on BIRC2, whereas others require inactivation of both genes in order to be sensitized to T cell challenge (1). The gene discussed is BIRC2; the disease is neoplasm.